About Inpharmatica
Inpharmatica is a company based in London (United Kingdom) founded in 1998 was acquired by Galapagos in December 2006.. The company has 62 employees as of January 31, 2021. Inpharmatica offers products and services including Chemogenomics, Druggability, and Silico. Inpharmatica operates in a competitive market with competitors including Insitro, Helix, Benchling, HotSpot Therapeutics and TOLREMO therapeutics, among others.
- Headquarter London, United Kingdom
- Employees 62 as on 31 Jan, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Galapagos Biotech Limited
- Date of Incorporation 08 Jul, 1997
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inpharmatica
Inpharmatica offers a comprehensive portfolio of products and services, including Chemogenomics, Druggability, and Silico. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Proprietary approach for identifying drug targets and libraries.
Assesses targets for lead chemistry potential in drug discovery.
Tools for early compound selection and property balancing.
Funding Insights of Inpharmatica
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $21.2M
-
First Round
First Round
(01 Jun 1998)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2017 | Amount | Post-IPO - Inpharmatica | Valuation |
investors |
|
| Nov, 2004 | Amount | Post-IPO - Inpharmatica | Valuation |
investors |
|
| Jul, 2001 | Amount | Post-IPO - Inpharmatica | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inpharmatica
Inpharmatica has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include GLPG, 3i Group and Gimv. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early to late-stage tech investments are made globally by REV.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Private equity firm focused on mid-market businesses
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inpharmatica
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inpharmatica
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inpharmatica Comparisons
Competitors of Inpharmatica
Inpharmatica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Helix, Benchling, HotSpot Therapeutics and TOLREMO therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Genomic database for clinical research is provided.
|
|
| domain | founded_year | HQ Location |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| domain | founded_year | HQ Location |
Developer of a platform for protein function analysis
|
|
| domain | founded_year | HQ Location |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| domain | founded_year | HQ Location |
Provider of a platform for in silico drug discovery and consulting services
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inpharmatica
Frequently Asked Questions about Inpharmatica
When was Inpharmatica founded?
Inpharmatica was founded in 1998.
Where is Inpharmatica located?
Inpharmatica is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Inpharmatica?
John Lisle is the current CEO of Inpharmatica.
How many employees does Inpharmatica have?
As of Jan 31, 2021, the latest employee count at Inpharmatica is 62.
What does Inpharmatica do?
Inpharmatica has developed a platform that uses predictive informatics in medicinal chemistry and ADME for drug discovery. The Chemagenomics platform is used for in silico target selection through drug assessment and identification of leads. The company also offers another platform called Silico used for ADME optimization, in silicon and in vitro assessments for identifying leads from hits.
Who are the top competitors of Inpharmatica?
Inpharmatica's top competitors include Insitro, Helix and HotSpot Therapeutics.
What products or services does Inpharmatica offer?
Inpharmatica offers Chemogenomics, Druggability, and Silico.
Who are Inpharmatica's investors?
Inpharmatica has 8 investors. Key investors include GLPG, 3i Group, Gimv, Abingworth, and REV.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.